SCHEMBL6819952

SCHEMBL6819952

CCO/C(=C\c1ccc(OCc2ccccc2)c(C(C)(C)C)c1)C(=O)O

nearest known ligand 0.47

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KDM4E B2RXH2 4/20 0.47
LMNA P02545 3/20 0.47
NR1H4 Q96RI1 1/20 0.46
RXRA P19793 1/20 0.46
RXRB P28702 1/20 0.46
RXRG P48443 1/20 0.46
ALDH1A1 P00352 4/20 0.44
HPGD P15428 2/20 0.43
APP P05067 4/20 0.43
MRGPRX4 Q96LA9 2/20 0.42
L3MBTL1 Q9Y468 3/20 0.41
POLB P06746 1/20 0.41
FFAR4 Q5NUL3 1/20 0.40
MAPT P10636 2/20 0.40
MAPK1 P28482 2/20 0.40
NTSR1 P30989 2/20 0.40
GAA P10253 1/20 0.40
PKM P14618 1/20 0.40
HTT P42858 1/20 0.40
PTGES O14684 1/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6819961 1.00 KDM4E (0.47) KDM4ELMNANR1H4RXRARXRB
SCHEMBL6816300 0.86 FFAR4 (0.52) KDM4ELMNANR1H4RXRARXRB
SCHEMBL6816289 0.86 FFAR4 (0.52) KDM4ELMNANR1H4RXRARXRB
SCHEMBL2138448 0.84 KDM4E (0.55) KDM4ELMNAALDH1A1HPGDAPP
SCHEMBL2138446 0.84 KDM4E (0.55) KDM4ELMNAALDH1A1HPGDAPP
SCHEMBL4878545 0.84 APP (0.60) KDM4ELMNAALDH1A1HPGDAPP
SCHEMBL4878539 0.84 APP (0.60) KDM4ELMNAALDH1A1HPGDAPP
SCHEMBL4878533 0.84 APP (0.60) KDM4ELMNAALDH1A1HPGDAPP
SCHEMBL811245 0.84 KDM4E (0.55) KDM4ELMNAALDH1A1HPGDAPP
SCHEMBL6819956 0.84 RXRA (0.48) KDM4ELMNARXRARXRBRXRG

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-6750252-B2 FOR USE IN CLINICAL CONDITIONS ASSOCIATED WITH INSULIN RESISTANCE ASTRAZENECA AB (SE) 2004-06-15 US disclosed
EP-1237856-B1 NEW TRI-SUBSTITUTED PHENYL DERIVATIVES AND ANALOGUES ASTRAZENECA AB (SE) 2004-05-12 EP disclosed
US-20030149104-A1 Tri-substituted phenyl derivatives and analogues ASTRAZENECA AB (SE) 2003-08-07 US disclosed
EP-1237856-A1 NEW TRI-SUBSTITUTED PHENYL DERIVATIVES AND ANALOGUES AstraZeneca AB (SE) 2002-09-11 EP disclosed
WO-2001040172-A1 NEW TRI-SUBSTITUTED PHENYL DERIVATIVES AND ANALOGUES ASTRAZENECA AB (SE) 2001-06-07 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20030149104-A1 Tri-substituted phenyl derivatives and analogues GPR119, IAPP, INSR KDM4E 3520/4885LMNA 1312/4885NR1H4 279/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.